Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | OGEN |
---|---|---|
09:32 ET | 5496 | 0.5105 |
09:34 ET | 4000 | 0.5407 |
09:41 ET | 500 | 0.520101 |
09:45 ET | 200 | 0.544749 |
09:48 ET | 184 | 0.5445 |
09:50 ET | 300 | 0.539 |
09:52 ET | 4650 | 0.52 |
09:54 ET | 3500 | 0.5324 |
09:56 ET | 100 | 0.5194 |
10:03 ET | 100 | 0.52 |
10:06 ET | 500 | 0.52 |
10:10 ET | 4497 | 0.516 |
10:12 ET | 567 | 0.516 |
10:14 ET | 200 | 0.516 |
10:17 ET | 1950 | 0.5299 |
10:19 ET | 1400 | 0.516 |
10:21 ET | 2500 | 0.516 |
10:26 ET | 200 | 0.516 |
10:28 ET | 3050 | 0.52 |
10:30 ET | 500 | 0.5178 |
10:32 ET | 600 | 0.5178 |
10:33 ET | 1296 | 0.516 |
10:44 ET | 500 | 0.516 |
10:48 ET | 400 | 0.516 |
10:55 ET | 400 | 0.516 |
10:57 ET | 400 | 0.516 |
11:00 ET | 500 | 0.516 |
11:08 ET | 400 | 0.516 |
11:09 ET | 399 | 0.516 |
11:20 ET | 775 | 0.5151 |
11:22 ET | 100 | 0.5119 |
11:24 ET | 1500 | 0.511 |
11:26 ET | 1662 | 0.5105 |
11:27 ET | 300 | 0.5105 |
11:33 ET | 200 | 0.5106 |
11:40 ET | 300 | 0.529805 |
11:42 ET | 329 | 0.5299 |
11:45 ET | 100 | 0.511 |
11:47 ET | 2640 | 0.5105 |
11:49 ET | 1553 | 0.5105 |
11:51 ET | 1600 | 0.5202 |
11:54 ET | 200 | 0.5105 |
11:58 ET | 4594 | 0.5105 |
12:00 ET | 1738 | 0.5105 |
12:05 ET | 200 | 0.5105 |
12:09 ET | 100 | 0.5105 |
12:16 ET | 2372 | 0.51 |
12:18 ET | 100 | 0.51 |
12:21 ET | 925 | 0.51495 |
12:23 ET | 100 | 0.51 |
12:27 ET | 194 | 0.515 |
12:34 ET | 493 | 0.51 |
12:39 ET | 100 | 0.5198 |
12:45 ET | 1903 | 0.51 |
12:50 ET | 6297 | 0.51 |
12:52 ET | 1603 | 0.505 |
12:57 ET | 700 | 0.505 |
12:59 ET | 100 | 0.505 |
01:10 ET | 6085 | 0.516727 |
01:12 ET | 51512 | 0.5 |
01:14 ET | 1119 | 0.482 |
01:15 ET | 22562 | 0.48 |
01:17 ET | 7228 | 0.48 |
01:19 ET | 1100 | 0.48 |
01:21 ET | 7934 | 0.48 |
01:26 ET | 2450 | 0.48 |
01:28 ET | 150 | 0.48 |
01:30 ET | 200 | 0.48 |
01:32 ET | 1000 | 0.4801 |
01:35 ET | 41383 | 0.5096 |
01:37 ET | 1300 | 0.485 |
01:44 ET | 2255 | 0.509599 |
01:46 ET | 302 | 0.509599 |
01:48 ET | 250 | 0.49 |
01:50 ET | 1000 | 0.5095 |
01:51 ET | 100 | 0.49 |
01:55 ET | 4898 | 0.49 |
02:00 ET | 200 | 0.4966 |
02:02 ET | 6100 | 0.49 |
02:04 ET | 11083 | 0.4999 |
02:06 ET | 2133 | 0.497 |
02:08 ET | 10900 | 0.49 |
02:09 ET | 671 | 0.5017 |
02:11 ET | 1020 | 0.49 |
02:13 ET | 6370 | 0.4887 |
02:15 ET | 5521 | 0.49 |
02:24 ET | 2853 | 0.49 |
02:26 ET | 100 | 0.5034 |
02:27 ET | 100 | 0.49 |
02:29 ET | 500 | 0.5034 |
02:31 ET | 784 | 0.49 |
02:33 ET | 100 | 0.5 |
02:36 ET | 500 | 0.497 |
02:38 ET | 2737 | 0.4971 |
02:40 ET | 507 | 0.5 |
02:47 ET | 2100 | 0.505 |
02:49 ET | 1500 | 0.5095 |
02:51 ET | 242 | 0.5073 |
02:54 ET | 1403 | 0.5094 |
02:56 ET | 2100 | 0.5082 |
03:00 ET | 5643 | 0.5091 |
03:02 ET | 1200 | 0.5044 |
03:18 ET | 1200 | 0.5044 |
03:30 ET | 700 | 0.5045 |
03:36 ET | 400 | 0.5117 |
03:39 ET | 1122 | 0.5051 |
03:41 ET | 200 | 0.5051 |
03:45 ET | 2954 | 0.5075 |
03:48 ET | 3078 | 0.5076 |
03:52 ET | 1458 | 0.5051 |
03:54 ET | 1050 | 0.5099 |
03:56 ET | 2467 | 0.504 |
03:57 ET | 6063 | 0.51 |
03:59 ET | 9913 | 0.5021 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Oragenics Inc | 4.3M | -0.1x | --- |
Hepion Pharmaceuticals Inc | 4.3M | -0.1x | --- |
Avenue Therapeutics Inc | 4.3M | -1.0x | --- |
Lixte Biotechnology Holdings Inc | 4.4M | -1.1x | --- |
Pasithea Therapeutics Corp | 4.4M | -0.3x | --- |
Transcode Therapeutics Inc | 4.4M | 0.0x | --- |
Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It is focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its lead product and focus is on the development and commercialization of ONP-002 for the treatment of mTBI.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.3M |
---|---|
Revenue (TTM) | $7.5K |
Shares Outstanding | 8.7M |
Oragenics Inc does not pay a dividend. | |
Beta | 0.64 |
EPS | $-6.99 |
Book Value | $1.03 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | 582.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -263,144.00% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.